Clarus Therapeutics Holdings, Inc. to Post FY2022 Earnings of ($1.32) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRXT)

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXTGet Rating) – Investment analysts at Cantor Fitzgerald raised their FY2022 earnings per share estimates for shares of Clarus Therapeutics in a research report issued to clients and investors on Tuesday, May 17th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($1.32) for the year, up from their previous forecast of ($1.98).

Clarus Therapeutics (NASDAQ:CRXTGet Rating) last announced its quarterly earnings results on Wednesday, March 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.49.

A number of other brokerages also recently issued reports on CRXT. Zacks Investment Research raised shares of Clarus Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Monday, April 4th. Needham & Company LLC decreased their price objective on shares of Clarus Therapeutics to $3.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Truist Financial decreased their price objective on shares of Clarus Therapeutics from $7.00 to $3.00 and set a “na” rating on the stock in a report on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Clarus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $8.79.

Shares of NASDAQ CRXT opened at $0.42 on Thursday. The company’s fifty day moving average price is $1.03 and its 200 day moving average price is $2.15. Clarus Therapeutics has a 1 year low of $0.41 and a 1 year high of $31.24.

Hedge funds and other institutional investors have recently modified their holdings of the company. Cowen AND Company LLC acquired a new stake in shares of Clarus Therapeutics in the third quarter valued at about $53,000. Citadel Advisors LLC acquired a new stake in shares of Clarus Therapeutics in the fourth quarter valued at about $31,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Clarus Therapeutics in the fourth quarter valued at about $51,000. Verition Fund Management LLC acquired a new stake in shares of Clarus Therapeutics in the third quarter valued at about $160,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Clarus Therapeutics in the first quarter valued at about $52,000. Institutional investors and hedge funds own 19.50% of the company’s stock.

Clarus Therapeutics Company Profile (Get Rating)

Clarus Therapeutics Holdings, Inc, a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.

Further Reading

Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.